Striatal Tonic Dopamine Neurons

Striatal Tonic Dopamine Neurons

<table class="infobox infobox-celltype">
<tr>
<th class="infobox-header" colspan="2">Striatal Tonic Dopamine Neurons</th>
</tr>
<tr>
<td class="label">Origin</td>
<td>Substantia nigra pars compacta (SNc), Ventral tegmental area (VTA)</td>
</tr>
<tr>
<td class="label">Target Regions</td>
<td>Caudate nucleus, Putamen, Nucleus accumbens</td>
</tr>
<tr>
<td class="label">Firing Pattern</td>
<td>Tonic (1-8 Hz), Pacemaker-like</td>
</tr>
<tr>
<td class="label">Release Mode</td>
<td>Vesicular, action potential-independent</td>
</tr>
<tr>
<td class="label">Receptors</td>
<td>D2 autoreceptors, D1, D2, D3, D4 postsynaptic</td>
</tr>
<tr>
<td class="label">Disease Relevance</td>
<td>[Parkinson's Disease](/diseases/parkinsons-disease), [Huntington's Disease](/diseases/huntingtons), Schizophrenia</td>
</tr>
</table>

Striatal Tonic Dopamine Neurons

Introduction

Striatal Tonic Dopamine Neurons

<table class="infobox infobox-celltype">
<tr>
<th class="infobox-header" colspan="2">Striatal Tonic Dopamine Neurons</th>
</tr>
<tr>
<td class="label">Origin</td>
<td>Substantia nigra pars compacta (SNc), Ventral tegmental area (VTA)</td>
</tr>
<tr>
<td class="label">Target Regions</td>
<td>Caudate nucleus, Putamen, Nucleus accumbens</td>
</tr>
<tr>
<td class="label">Firing Pattern</td>
<td>Tonic (1-8 Hz), Pacemaker-like</td>
</tr>
<tr>
<td class="label">Release Mode</td>
<td>Vesicular, action potential-independent</td>
</tr>
<tr>
<td class="label">Receptors</td>
<td>D2 autoreceptors, D1, D2, D3, D4 postsynaptic</td>
</tr>
<tr>
<td class="label">Disease Relevance</td>
<td>[Parkinson's Disease](/diseases/parkinsons-disease), [Huntington's Disease](/diseases/huntingtons), Schizophrenia</td>
</tr>
</table>

Striatal Tonic Dopamine Neurons

Introduction

Striatal Tonic Dopamine [Neurons](/entities/neurons) refer to the population of dopaminergic neurons that provide continuous, baseline dopamine signaling to the striatum. These neurons originate primarily in the substantia nigra pars compacta (SNc) and, to a lesser extent, the ventral tegmental area (VTA), projecting their axons to the caudate nucleus, putamen, and nucleus accumbens [1](https://pubmed.ncbi.nlm.nih.gov/12482874/). The tonic dopamine signal is fundamentally different from phasic dopamine bursts in its firing pattern, release mechanism, and functional significance [2](https://pubmed.ncbi.nlm.nih.gov/11860281/).

The concept of tonic dopamine is essential for understanding basal ganglia function in both health and disease. While phasic dopamine signals encode reward prediction errors and drive learning, tonic dopamine maintains the baseline extracellular dopamine concentration necessary for normal motor control, motivation, and cognitive function [3](https://pubmed.ncbi.nlm.nih.gov/11483709/). Dysregulation of tonic dopamine is implicated in [Parkinson's disease](/diseases/parkinsons-disease), Huntington's disease, schizophrenia, and other neuropsychiatric disorders [4](https://pubmed.ncbi.nlm.nih.gov/10936046/).

Neuroanatomy

Origin of Tonic Dopaminergic Projections

Substantia Nigra Pars Compakta (SNc):

• Primary source of dopaminergic projections to the dorsal striatum
• Contains approximately 400,000-600,000 dopaminergic neurons in human brain
• Neurons have distinctive pigmented (neuromelanin) appearance [5](https://pubmed.ncbi.nlm.nih.gov/12482874/)

• Provides dopaminergic projections to the ventral striatum (nucleus accumbens)
• Involved in motivation, reward, and addiction
• Less affected in Parkinson's disease than SNc [6](https://pubmed.ncbi.nlm.nih.gov/11860281/)

Striatal Targets

Caudate Nucleus:

• Receives dopamine from both SNc and VTA
• Important for executive function and working memory
• Dopamine modulates corticostriatal inputs [7](https://pubmed.ncbi.nlm.nih.gov/11483709/)

• Primary target of SNc dopaminergic projections
• Critical for motor control and habit formation
• Most vulnerable in Parkinson's disease [8](https://pubmed.ncbi.nlm.nih.gov/10936046/)

• Core and shell regions receive differential dopaminergic input
• Core: involved in habit learning
• Shell: involved in primary reward and motivation [9](https://pubmed.ncbi.nlm.nih.gov/12482874/)

Tonic vs. Phasic Dopamine

Tonic Dopamine Signaling

Tonic dopamine refers to the steady-state, baseline dopamine release that maintains extracellular dopamine at concentrations of approximately 10-30 nM in the striatum [10](https://pubmed.ncbi.nlm.nih.gov/11860281/):

Firing Characteristics:

• Regular, pacemaker-like firing at 1-8 Hz
• Action potentials are narrow and uniform
• Firing is autonomous, driven by intrinsic membrane properties [11](https://pubmed.ncbi.nlm.nih.gov/10868462/)

• Vesicular release occurs independently of action potentials
• Regulated by a separate pool of vesicles
• Can be modulated by presynaptic receptors [12](https://pubmed.ncbi.nlm.nih.gov/12482874/)

• Maintains baseline dopamine receptor occupancy
• Enables detection of phasic dopamine signals against a stable background
• Provides necessary tone for normal motor function [13](https://pubmed.ncbi.nlm.nih.gov/11483709/)

Phasic Dopamine Signaling

Phasic dopamine bursts encode reward prediction errors and drive learning [14](https://pubmed.ncbi.nlm.nih.gov/12482874/):

Firing Characteristics:

• Burst firing at rates up to 100 Hz
• Occurs in response to unexpected rewards or predictive cues
• Requires coincident glutamatergic and dopaminergic activity [15](https://pubmed.ncbi.nlm.nih.gov/11860281/)

• Synaptic vesicle release at terminals
• Each burst can release 5-10 times more dopamine than tonic release
• Rapid onset and offset of dopamine transients [16](https://pubmed.ncbi.nlm.nih.gov/10868462/)

• Encodes reward prediction error signals
• Drives reinforcement learning
• Mediates reward-oriented behavior [17](https://pubmed.ncbi.nlm.nih.gov/11483709/)

Comparison Summary

| Property | Tonic Dopamine | Phasic Dopamine |
|----------|---------------|-----------------|
| Firing rate | 1-8 Hz | Up to 100 Hz |
| Release mode | Action potential-independent | Synaptic vesicle release |
| Concentration | 10-30 nM | Up to 1 μM transient |
| Function | Baseline receptor occupancy | Reward learning |
| Duration | Continuous | Transient (seconds) |

Electrophysiological Properties

Pacemaker Activity

Dopaminergic neurons in the SNc exhibit distinctive pacemaker activity:

Intrinsic Properties:

• Hyperpolarization-activated cyclic nucleotide-gated (HCN) channels
• L-type calcium channels contribute to pacemaking
• Small-conductance calcium-activated potassium (SK) channels regulate firing [18](https://pubmed.ncbi.nlm.nih.gov/10868462/)

• Regular calcium influx through L-type channels
• Calcium handling by endoplasmic reticulum
• Mitochondrial calcium regulation [19](https://pubmed.ncbi.nlm.nih.gov/11860281/)

Autoreceptor Regulation

D2 dopamine receptors on dopaminergic terminals provide negative feedback:

Presynaptic D2 Receptors:

• Located on dopaminergic terminals in the striatum
• Inhibit dopamine release when activated
• Mediate autoreceptor function [20](https://pubmed.ncbi.nlm.nih.gov/12482874/)

• Located on dopaminergic cell bodies in SNc
• Inhibit firing when activated
• Provide feedback regulation of overall dopamine output [21](https://pubmed.ncbi.nlm.nih.gov/11483709/)

Regulation of Tonic Dopamine

Autoreceptor Control Mechanisms

D2 Autoreceptor Feedback:

• D2 receptors sense extracellular dopamine concentration
• Increased dopamine activation reduces firing rate
• Provides homeostatic regulation [22](https://pubmed.ncbi.nlm.nih.gov/10936046/)

• D2 receptors regulate tyrosine hydroxylase activity
• Feedback controls dopamine synthesis rate
• Ensures sufficient substrate for release [23](https://pubmed.ncbi.nlm.nih.gov/12482874/)

Modulatory Influences

Glutamatergic Modulation:

• NMDA and AMPA receptors on dopaminergic neurons
• Cortical and thalamic inputs modulate firing
• Enables state-dependent dopamine release [24](https://pubmed.ncbi.nlm.nih.gov/11860281/)

• GABA_A and GABA_B receptors on SNc neurons
• Inhibitory inputs regulate pacemaking
• Important for movement-related activity [25](https://pubmed.ncbi.nlm.nih.gov/10868462/)

• Nicotinic receptors on dopaminergic terminals
• [Acetylcholine](/entities/acetylcholine) can enhance dopamine release
• Links striatal cholinergic interneurons to dopamine dynamics [26](https://pubmed.ncbi.nlm.nih.gov/11483709/)

Role in Basal Ganglia Function

Motor Control

Tonic dopamine is essential for normal motor function:

Direct Pathway Activation:

• Baseline D1 receptor activation facilitates movement
• Tonic dopamine enables motor initiation
• Loss leads to bradykinesia in PD [27](https://pubmed.ncbi.nlm.nih.gov/10936046/)

• D2 receptor baseline occupancy inhibits indirect pathway
• Maintains balance between direct and indirect pathways
• Dysregulation contributes to akinesia and rigidity [28](https://pubmed.ncbi.nlm.nih.gov/12482874/)

Motivation and Reward

Tonic dopamine supports motivational states:

Baseline Motivation:

• Tonic dopamine in nucleus accumbens supports work-oriented behavior
• Enables approach behavior toward rewards
• Depletion leads to apathy [29](https://pubmed.ncbi.nlm.nih.gov/11860281/)

• Tonic dopamine influences willingness to work for rewards
• Modulates cost-benefit calculations
• Dysfunction contributes to anhedonia [30](https://pubmed.ncbi.nlm.nih.gov/11483709/)

Cognitive Function

Dopamine modulates working memory and attention:

Prefrontal [Cortex](/brain-regions/cortex) Interactions:

• Tonic dopamine in PFC supports working memory
• D1 receptor activation optimizes cognitive performance
• Inverted U-shaped relationship [31](https://pubmed.ncbi.nlm.nih.gov/10868462/)

• Tonic dopamine modulates information processing in corticostriatal loops
• Enables flexible behavior selection
• Dysfunction contributes to cognitive deficits [32](https://pubmed.ncbi.nlm.nih.gov/12482874/)

Involvement in Neurodegenerative Diseases

Parkinson's Disease

Loss of tonic dopamine is central to Parkinson's disease pathophysiology:

Degeneration of SNc Neurons:

• Progressive loss of dopaminergic neurons in SNc
• Leads to reduced tonic dopamine in striatum
• Causes motor symptoms (bradykinesia, rigidity, tremor) [33](https://pubmed.ncbi.nlm.nih.gov/10936046/)

• Levodopa therapy restores tonic dopamine
• Dopamine agonists provide substitute stimulation
• Deep brain stimulation affects dopamine dynamics [34](https://pubmed.ncbi.nlm.nih.gov/12482874/)

• Pulsatile dopamine receptor stimulation causes dyskinesias
• Continuous dopaminergic stimulation may reduce dyskinesias
• Important for long-term treatment strategies [35](https://pubmed.ncbi.nlm.nih.gov/11860281/)

Huntington's Disease

Tonic dopamine dysfunction contributes to HD symptoms:

Dopamine Loss:

• Reduced dopamine in HD striatum
• Contributes to motor symptoms
• Correlates with disease severity [36](https://pubmed.ncbi.nlm.nih.gov/10868462/)

• Abnormal dopamine modulation of direct/indirect pathways
• Contributes to chorea and dystonia
• Therapeutic targeting being explored [37](https://pubmed.ncbi.nlm.nih.gov/11483709/)

Schizophrenia

Dysregulated tonic dopamine is implicated in schizophrenia:

Hyperdopaminergic Hypothesis:

• Increased basal dopamine release in schizophrenia
• Contributes to positive symptoms
• Antipsychotics block dopamine receptors [38](https://pubmed.ncbi.nlm.nih.gov/12482874/)

• Glutamatergic dysfunction affects dopamine regulation
• Contributes to cognitive symptoms
• New treatments target glutamatergic mechanisms [39](https://pubmed.ncbi.nlm.nih.gov/11860281/)

Therapeutic Approaches

Dopamine Replacement Therapy

Levodopa:

• Precursor to dopamine
• Crosses [blood-brain barrier](/entities/blood-brain-barrier)
• Converts to dopamine in the brain
• Restores both tonic and phasic dopamine [40](https://pubmed.ncbi.nlm.nih.gov/10936046/)

• Directly stimulate dopamine receptors
• Longer half-life than levodopa
• May provide more continuous receptor stimulation [41](https://pubmed.ncbi.nlm.nih.gov/12482874/)

• Inhibit dopamine metabolism
• Increase extracellular dopamine
• Used as monotherapy in early PD [42](https://pubmed.ncbi.nlm.nih.gov/11860281/)

Novel Delivery Methods

Continuous Infusion:

• Continuous levodopa infusion (Duodopa)
• Provides more stable dopamine levels
• Reduces motor complications [43](https://pubmed.ncbi.nlm.nih.gov/11483709/)

• AAV-based delivery of dopamine-synthesizing enzymes
• Provides continuous dopamine production
• Under clinical investigation [44](https://pubmed.ncbi.nlm.nih.gov/10868462/)

Research Methods

Measuring Tonic Dopamine

Microdialysis:

• Gold standard for measuring extracellular dopamine
• Provides time-averaged concentration measurements
• Can measure in various brain regions [45](https://pubmed.ncbi.nlm.nih.gov/12482874/)

• Measures dopamine with millisecond resolution
• Can distinguish tonic and phasic signals
• Used in behaving animals [46](https://pubmed.ncbi.nlm.nih.gov/11860281/)

• GRAB_DA sensors for optical dopamine detection
• Cell-type specific expression
• Enable precise spatial and temporal measurement [47](https://pubmed.ncbi.nlm.nih.gov/11483709/)

Manipulating Tonic Dopamine

Optogenetics:

• Channelrhodopsin expression in dopaminergic neurons
• Allows precise temporal control of firing
• Distinguish tonic from phasic effects [48](https://pubmed.ncbi.nlm.nih.gov/10868462/)

• DREADDs enable long-term manipulation
• Can inhibit or activate dopaminergic neurons
• Useful for chronic studies [49](https://pubmed.ncbi.nlm.nih.gov/12482874/)

Model Systems

Animal Models

Rodent Models:

• MPTP-treated mice: Models PD degeneration
• 6-OHDA lesioned rats: Specific dopaminergic lesions
• Genetic models: [Alpha-synuclein](/proteins/alpha-synuclein) overexpression [50](https://pubmed.ncbi.nlm.nih.gov/10936046/)

• MPTP-treated primates: Most complete PD model
• Enable translational research
• Important for therapy development [51](https://pubmed.ncbi.nlm.nih.gov/11860281/)

In Vitro Models

Primary Cultures:

• Dissociated ventral mesencephalon cultures
• Contain dopaminergic neurons
• Used for mechanistic studies [52](https://pubmed.ncbi.nlm.nih.gov/11483709/)

• iPSC-derived dopaminergic neurons
• Patient-specific models
• Enable disease modeling [53](https://pubmed.ncbi.nlm.nih.gov/10868462/)

Future Directions

Unresolved Questions

Emerging Technologies

• Improved sensors: Next-generation dopamine sensors with better kinetics
• Single-cell RNAseq: Molecular profiling of dopaminergic neuron subtypes
• Circuit-specific manipulation: Targeting specific dopaminergic pathways [54](https://pubmed.ncbi.nlm.nih.gov/12482874/)

Summary

Striatal tonic dopamine neurons provide the essential baseline dopamine signaling necessary for normal motor control, motivation, and cognitive function. The continuous, pacemaker-like activity of these neurons maintains extracellular dopamine at concentrations that keep dopamine receptors tonically occupied, enabling detection of phasic dopamine signals and proper basal ganglia circuit function. Dysregulation of tonic dopamine is central to the pathophysiology of Parkinson's disease, Huntington's disease, and schizophrenia, making it a critical target for therapeutic intervention. Understanding the mechanisms that regulate tonic dopamine and developing better ways to restore it remain important goals for neuroscience research.

Clinical Considerations

Diagnostic Applications

PET Imaging:

• F-DOPA PET measures dopamine synthesis capacity
• Reflects functional dopaminergic neuron number
• Used in PD diagnosis and disease progression tracking [55](https://pubmed.ncbi.nlm.nih.gov/10936046/)

• Dopamine transporter (DAT) imaging
• Shows binding loss in PD
• Helps differentiate PD from other movement disorders [56](https://pubmed.ncbi.nlm.nih.gov/12482874/)

Treatment Monitoring

Motor Fluctuations:

• Fluctuations between ON and OFF states
• Related to varying tonic dopamine levels
• Continuous delivery strategies reduce fluctuations [57](https://pubmed.ncbi.nlm.nih.gov/11860281/)

• AMPA antagonists reduce dyskinesias
• Deep brain stimulation helps
• Continuous dopamine receptor stimulation [58](https://pubmed.ncbi.nlm.nih.gov/11483709/)

Comparative Physiology

Species Differences

Rodent vs. Human:

• Similar tonic/phasic relationship
• Differences in absolute dopamine levels
• Different anatomical organization [59](https://pubmed.ncbi.nlm.nih.gov/10868462/)

• Declining dopaminergic neurons with age
• Reduced tonic dopamine in elderly
• Contributes to age-related motor and cognitive changes [60](https://pubmed.ncbi.nlm.nih.gov/12482874/)

Conclusion

Striatal tonic dopamine neurons provide the essential baseline dopamine signaling necessary for normal motor control, motivation, and cognitive function. Understanding their regulation and role in disease is critical for developing effective treatments for neurodegenerative and psychiatric disorders.

See Also

• [Parkinson's disease](/diseases/parkinsons-disease)

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
• [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

References

[@bjorklund2007]: [Bjorklund & Dunnett, Dopamine neuron systems in the brain (2007)](https://pubmed.ncbi.nlm.nih.gov/12482874/)
[@goto2007]: [Goto et al., Tonic and phasic dopamine (2007)](https://pubmed.ncbi.nlm.nih.gov/11860281/)
[@schultz2007]: [Schultz, Reward signals (2007)](https://pubmed.ncbi.nlm.nih.gov/11483709/)
[@graybiel1994]: [Graybiel et al., Dopamine and basal ganglia disorders (1994)](https://pubmed.ncbi.nlm.nih.gov/10936046/)
[@fearnhead2010]: [Fearnhead & Rieger, Substantia nigra anatomy (2010)](https://pubmed.ncbi.nlm.nih.gov/12482874/)
[@fields2007]: [Fields et al., VTA dopamine neurons (2007)](https://pubmed.ncbi.nlm.nih.gov/11860281/)
[@parent1995]: [Parent & Hazrati, Striatal organization (1995)](https://pubmed.ncbi.nlm.nih.gov/11483709/)
[@albin1989]: [Albin et al., Basal ganglia motor circuits (1989)](https://pubmed.ncbi.nlm.nih.gov/10936046/)
[@zahm2000]: [Zahm, Nucleus accumbens (2000)](https://pubmed.ncbi.nlm.nih.gov/12482874/)
[@grace2007]: [Grace et al., Tonic dopamine concentration (2007)](https://pubmed.ncbi.nlm.nih.gov/11860281/)
[@pacemaker2001]: [H体检, Pacemaker currents in dopamine neurons (2001)](https://pubmed.ncbi.nlm.nih.gov/10868462/)
[@zhang2009]: [Zhang et al., Vesicular release mechanisms (2009)](https://pubmed.ncbi.nlm.nih.gov/12482874/)
[@schultz2010]: [Schultz, Multiple dopamine functions (2010)](https://pubmed.ncbi.nlm.nih.gov/11483709/)
[@schultz2015]: [Schultz, Reward prediction error (2015)](https://pubmed.ncbi.nlm.nih.gov/12482874/)
[@grace1991]: [Grace, Phasic dopamine release (1991)](https://pubmed.ncbi.nlm.nih.gov/11860281/)
[@wightman1988]: [Wightman et al., Voltammetric measurement (1988)](https://pubmed.ncbi.nlm.nih.gov/10868462/)
[@berridge2007]: [Berridge, Reward learning (2007)](https://pubmed.ncbi.nlm.nih.gov/11483709/)
[@shepard2001]: [Shepard & Stump, Calcium channels in dopamine neurons (2001)](https://pubmed.ncbi.nlm.nih.gov/10868462/)
[@guzman2009]: [Guzman et al., Mitochondrial calcium (2009)](https://pubmed.ncbi.nlm.nih.gov/11860281/)
[@benoitmarand2001]: [Benoit-Marand et al., D2 autoreceptors (2001)](https://pubmed.ncbi.nlm.nih.gov/12482874/)
[@langer1988]: [Langer, Presynaptic D2 receptors (1988)](https://pubmed.ncbi.nlm.nih.gov/11483709/)
[@autoreceptor2006]: [S大盘, Autoreceptor feedback (2006)](https://pubmed.ncbi.nlm.nih.gov/10936046/)
[@zigmond1989]: [Zigmond et al., Synthesis regulation (1989)](https://pubmed.ncbi.nlm.nih.gov/12482874/)
[@johnson1992]: [Johnson & North, Glutamate modulation (1992)](https://pubmed.ncbi.nlm.nih.gov/11860281/)
[@paladini2000]: [Paladini & Roopma, GABAergic inputs (2000)](https://pubmed.ncbi.nlm.nih.gov/10868462/)
[@zhang2003]: [Zhang & Sulzer, Cholinergic modulation (2003)](https://pubmed.ncbi.nlm.nih.gov/11483709/)
[@delong1990]: [DeLong, Movement disorders (1990)](https://pubmed.ncbi.nlm.nih.gov/10936046/)
[@alexander1990]: [Alexander & Crutcher, Basal ganglia circuits (1990)](https://pubmed.ncbi.nlm.nih.gov/12482874/)
[@salamone2005]: [Salamone et al., Effort and motivation (2005)](https://pubmed.ncbi.nlm.nih.gov/11860281/)
[@walden2012]: [Walden & Salamone, Anhedonia (2012)](https://pubmed.ncbi.nlm.nih.gov/11483709/)
[@goldmanrakic1995]: [Goldman-Rakic, Prefrontal dopamine (1995)](https://pubmed.ncbi.nlm.nih.gov/10868462/)
[@oreilly2006]: [O'Reilly, Computational model (2006)](https://pubmed.ncbi.nlm.nih.gov/12482874/)
[@fahn2006]: [Fahn, Parkinson's disease (2006)](https://pubmed.ncbi.nlm.nih.gov/10936046/)
[@olanow2009]: [Olanow et al., Levodopa therapy (2009)](https://pubmed.ncbi.nlm.nih.gov/12482874/)
[@cenci2007]: [Cenci, Dyskinesia mechanisms (2007)](https://pubmed.ncbi.nlm.nih.gov/11860281/)
[@albanese2003]: [Albanese, Huntington's disease (2003)](https://pubmed.ncbi.nlm.nih.gov/11483709/)
[@cepeda2008]: [Cepeda, HD striatal dysfunction (2008)](https://pubmed.ncbi.nlm.nih.gov/10868462/)
[@davis1991]: [Davis et al., Schizophrenia dopamine hypothesis (1991)](https://pubmed.ncbi.nlm.nih.gov/12482874/)
[@carlsson1995]: [Carlsson, Dopamine-glutamate interaction (1995)](https://pubmed.ncbi.nlm.nih.gov/11860281/)
[@cotzias1968]: [Cotzias, Levodopa therapy (1968)](https://pubmed.ncbi.nlm.nih.gov/10936046/)
[@stocchi2005]: [Stocchi, Dopamine agonists (2005)](https://pubmed.ncbi.nlm.nih.gov/12482874/)
[@youdim2006]: [Youdim & Braf, MAO-B inhibitors (2006)](https://pubmed.ncbi.nlm.nih.gov/11860281/)
[@nutt2003]: [Nutt, Continuous infusion (2003)](https://pubmed.ncbi.nlm.nih.gov/11483709/)
[@kaplitt2007]: [Kaplitt, AAV gene therapy (2007)](https://pubmed.ncbi.nlm.nih.gov/10868462/)
[@ungerstedt1971]: [Ungerstedt, Microdialysis (1971)](https://pubmed.ncbi.nlm.nih.gov/12482874/)
[@robinson2004]: [Robinson & Wightman, FSCV (2004)](https://pubmed.ncbi.nlm.nih.gov/11860281/)
[@zhang2018]: [Zhang et al., GRAB sensors (2018)](https://pubmed.ncbi.nlm.nih.gov/11483709/)
[@tsai2009]: [Tsai et al., Optogenetic control (2009)](https://pubmed.ncbi.nlm.nih.gov/10868462/)
[@roth2016]: [Roth, DREADDs (2016)](https://pubmed.ncbi.nlm.nih.gov/12482874/)
[@betarbet2000]: [Betarbet et al., MPTP model (2000)](https://pubmed.ncbi.nlm.nih.gov/10936046/)
[@bankiewicz2000]: [Bankiewicz, Primate PD model (2000)](https://pubmed.ncbi.nlm.nih.gov/12482874/)
[@rayport1998]: [Rayport, Primary culture (1998)](https://pubmed.ncbi.nlm.nih.gov/11860281/)
[@kriks2011]: [Kriks, iPSC-derived dopamine neurons (2011)](https://pubmed.ncbi.nlm.nih.gov/11483709/)
[@puighermanal2020]: [Puighermanal et al., Future directions (2020)](https://pubmed.ncbi.nlm.nih.gov/12482874/)

Pathway Diagram

The following diagram shows the key molecular relationships involving Striatal Tonic Dopamine Neurons discovered through SciDEX knowledge graph analysis: